Premium
Serum methotrexate and human chorionic gonadotropin concentrations during five‐day chemotherapy for low‐risk metastatic gestational trophoblastic neoplasia
Author(s) -
Hilgers R.D.,
Standefer J.C.,
Bowling M.C.,
Greeley P.
Publication year - 1988
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/0020-7292(88)90124-5
Subject(s) - medicine , methotrexate , human chorionic gonadotropin , chorioepithelioma , chemotherapy , obstetrics , gestation , gonadotropin , gynecology , pregnancy , choriocarcinoma , oncology , hormone , biology , genetics
Abstract A recent report of serum methotrexate (MTX) levels measured during treatment of gestational trophoblastic neoplasia (GTN) led us to determine MTX and human chorionic gonadotropin (β‐hCG) levels in a patient with low‐risk metastatic GTN with a pulmonary metastasis. Peak MTX concentrations exceeded 10 −6 mol/l considered by many investigators to be within the therapeutic range against many human tumors. Serum β‐hCG levels did not decline during MTX administration; however, after 5 days of MTX a steep dose‐response curve was observed which continued during 5 courses of chemotherapy.